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Move Over Myxoma*Kirsten E. Fleischmann, MD, MPH, Nelson B. Schiller, MDP apillary ﬁbroelastomas are small, frond-like,often stalked intracardiac tumors known fortheir embolic potential. In 1975, while at
Armed Forces Institute of Pathology, our colleague
Melvin Cheitlin and his group appear to have been
the ﬁrst to publish the term “papillary ﬁbroelastoma”
in a case report of an embolic myocardial infarction
in the absence of atherosclerosis (1). Since that
description, the optimal management of these benign
masses, particularly in asymptomatic patients, has
been debated, in part because therapy often consists
of surgical removal with all its attendant risks, and
in part because the rarity of these tumors has pro-
vided scant evidence on which to base diagnostic
and treatment decisions. There is disagreement
regarding the use of the terms “tumor” or “neoplasm”
to describe these masses (M. Cheitlin, personal
communication, April 2015); for the sake of discus-
sion but not dogma, we will take the position that
papillary ﬁbroelastoma is a benign tumor. In doing
so, we hope to stimulate discussion that might
improve understanding about its appropriate desig-
nation in cardiac pathology.The report of Tamin et al. (2) in this issue of the
Journal is welcome as the largest single series of this
entity yet reported, although a prior meta-analysis
included more cases in total (3). In more than 500
cases of presumed ﬁbroelastoma spanning a 16-year
period at the Mayo Clinic, 185 patients had their tu-
mors surgically resected, either as a primary excision
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From the Department of Medicine, Division of Cardiology, University of
California-San Francisco, San Francisco, California. Both authors have
reported that they have no relationships relevant to the contents of this
paper to disclose.(51%) or as an accoutrement to other surgery (49%).
These patients are contrasted with the 326 patients
whose echocardiograms suggested papillary ﬁbroe-
lastoma, but no surgical resection or pathological
examination was performed to conﬁrm the diagnosis.
Roughly one-third (32%) of the surgical group had
experienced a transient ischemic attack or stroke. As
in prior series (3,4), most tumor-like masses were
found on valves, with the aortic valve being the single
most common site, and in 98% of the surgical group,
the native valve could be preserved. Similarly, in
the group that was conservatively managed without
surgery, 38% of patients had a previous neurologic
event. The reasons for the choice of surgical versus
conservative management are not entirely trans-
parent in this report, but we do know that patients
who were treated surgically had larger ﬁbroelasto-
mas, on average, than those treated conservatively
(9.76 mm vs. 7.57 mm, respectively). As might be
expected, papillary ﬁbroelastomas in patients whose
presenting symptom was a neurological event were
smaller than those in patients who were imaged for
other indications and identiﬁed incidentally (7.1 mm
vs. 8.95 mm, respectively).
The report by Tamin et al. (2) has several lessons
for the practicing clinician. First, in this highly-
selected referral population, papillary ﬁbroelastoma
was actually more prevalent (0.089% of all echocar-
diograms) than myxoma, generally thought to be
the most common primary intracardiac tumor on the
basis of autopsy series (5,6). Although selected, this
unexpected ﬁnding suggests that whereas cardiac
tumors as a whole remain rare entities, papillary
ﬁbroelastomas may be considerably better repre-
sented than previously thought.
Diagnostically, roughly one-half of the cohort un-
derwent both transthoracic echocardiography (TTE)
and transesophageal echocardiography (TEE). Of
these, approximately one-third of the lesions were
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2431seen only on TEE. This suggests that routine TTE for
other indications likely misses a sizeable proportion
of asymptomatic papillary ﬁbroelastomas not linked
to neurological or other embolic events. These data
also support proceeding to TEE when the clinical in-
dex of suspicion for papillary ﬁbroelastoma or other
source of embolism is high, even when TTE is nega-
tive. This observation also reinforces the designation
of ﬁbroelastoma as the most common benign cardiac
tumor. Importantly, most ﬁbroelastomas were not
associated with valvular dysfunction (82%), and
when present, valve dysfunction was usually due to
other causes.
However, the heart of this report is in its longer-
term follow-up data. Over a median follow-up of
1.6 years, roughly two-thirds of surgical patients had
follow-up echocardiogram(s), and evidence of recur-
rent papillary ﬁbroelastoma was present in 3 patients
(1.6%), a ﬁnding that has not been previously re-
ported (4). Post-operatively, the risk of stroke in the
surgical group was 2% at 1 year and 8% at 5 years,
with 10 observed strokes as compared with the
expected 4 strokes in age- and sex-matched control
subjects. In contrast, in the nonsurgical group
(median follow-up 1.7 years), the risk of stroke was
6% and 13% at 1 and 5 years, respectively, with 29
strokes compared with just more than 8 expected
strokes on the basis of incidence in matched control
subjects. However, almost all patients in the non-
surgical group had other risk factors for stroke,
such as hypertension, atrial ﬁbrillation, or athero-
sclerosis, and data on how many of these events were
truly embolic is lacking. Unfortunately, unlike prior
reports, echocardiographic features did not pre-
dict stroke risk, so imaging, although diagnostically
important, could not be effectively used to stratify
the patient’s risk for adverse events. A survey of
medical therapy in these patients is also reported;
there was no signiﬁcant difference in stroke risk
among those treated with anticoagulation, anti-
platelet agents, or neither, but the study is likely
underpowered to detect a difference.
Direct comparison of the cohort undergoing sur-
gery and those treated conservatively is difﬁcult, as
the decision to refer to surgery was at the discretion
of the treating physician, and patients who were
referred to surgery differed from others on several
important features. For example, surgical patients
were younger (mean age 63 years vs. 67 years in the
nonsurgical group); had a signiﬁcantly lower inci-
dence of hypertension, prior stroke, previous rheu-
matic heart disease, prior radiation therapy, or
immunosuppression; and had a higher incidence of
prior endocarditis. The authors used a sophisticatedmodeling technique called propensity analysis to try
to account for factors associated with surgical inter-
vention. On the basis of their analysis, mortality in
the surgical group was lower than in conservatively-
managed patients (hazard ratio: 0.68), although this
was only statistically signiﬁcant in a parallel Cox
regression analysis. There was no signiﬁcant dif-
ference in mortality between those who underwent
surgery primarily for ﬁbroelastoma and those in
whom there was another primary surgical indication.
However, mortality in those who were referred to
surgery primarily for their ﬁbroelastoma was lower
than in the nonsurgical group, whereas mortality in
those with other primary surgical indications did not
differ signiﬁcantly from that of nonsurgical patients.
The risk of stroke, although also elevated above ex-
pected levels in the surgical group, was reportedly
signiﬁcantly higher in the conservatively-managed
group versus published age- and sex-matched data
from the American Heart Association (2,7).
The authors use this analysis, along with the
excellent surgical results reported, to propose an
aggressive surgical approach to presumed papillary
ﬁbroelastoma. First, a thorough workup for other
potential entities, such as endocarditis, lupus, or
antiphospholipid antibody syndrome, is undertaken.
Then, all patients who are surgical candidates in an
“expert surgical center” would undergo removal with
periodic surveillance for recurrence. Patients who
were not surgical candidates or who had increased
interventional risks would be treated with antiplate-
let agents. One issue, of course, is that despite careful
analysis, the data on which this approach is based are
prone to referral, veriﬁcation, and other biases. Also,
other centers may not be able to achieve the excellent
surgical results in this report. Moreover, validation of
such an approach is currently lacking. Therefore, we
would agree with Tamin et al. (2) that further data on
this issue is needed, particularly in asymptomatic
patients and preferably from randomized multi-
center trials. Until then, clinicians will continue to
assess patients with echocardiographically-diagnosed
papillary ﬁbroelastoma on a case-by-case basis, with
surgical intervention for those in whom the beneﬁt–
risk ratio appears favorable.
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